On the architecture of translational research designed to control chronic lymphocytic leukemia

被引：11
作者：
Hallek, Michael [1 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2018年
关键词：
MINIMAL RESIDUAL DISEASE; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; INTERNATIONAL PROGNOSTIC INDEX; PREVIOUSLY UNTREATED PATIENTS; CELL ANTIGEN RECEPTOR; PHASE-III TRIAL; LRF CLL4 TRIAL; INITIAL THERAPY; OPEN-LABEL; INDEPENDENT PREDICTOR;
D O I：
10.1182/asheducation-2018.1.1
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
Chronic lymphocytic leukemia (CLL) has been 1 of the most dynamic fields of clinical research over the last 2 decades. Important advances in understanding the biology of CLL have led to the development of new prognostic and diagnostic tools. Concurrently, several recently approved new agents hold the potential to fundamentally change the management of this leukemia and have started to improve clinical outcomes for patients. This conceptual review summarizes the major recent insights regarding the biology of CLL, the technological advances that have allowed refinement of the prognostication of the clinical course, and the new therapeutic strategies that are currently under investigation to further ameliorate the outcome for patients with CLL.
引用
收藏
页码：1 / 8
页数：8
相关论文
共 50 条
  • [31] Current Treatment of Chronic Lymphocytic Leukemia
    Jamroziak, Krzysztof
    Pula, Bartosz
    Walewski, Jan
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [32] Sequencing of chronic lymphocytic leukemia therapies
    Barrientos, Jacqueline C.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 128 - 136
  • [33] Lenalidomide in the treatment of chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (05) : 633 - 650
  • [34] Chronic Lymphocytic Leukemia
    Chiorazzi, Nicholas
    Chen, Shih-Shih
    Rai, Kanti R.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (02): : 1 - 35
  • [35] Personalizing treatment for chronic lymphocytic leukemia
    Abrisqueta, Pau
    Crespo, Marta
    Bosch, Francesc
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 27 - 35
  • [36] Chronic Lymphocytic Leukemia: Current Concepts
    Yu, Eun-Mi
    Kittai, Adam
    Tabbara, Imad A.
    ANTICANCER RESEARCH, 2015, 35 (10) : 5149 - 5165
  • [37] OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Rogers, K. A.
    Jones, J. A.
    DRUGS OF TODAY, 2014, 50 (06) : 407 - 419
  • [38] Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia
    Innocenti, Idanna
    Autore, Francesco
    Pasquale, Raffaella
    Morelli, Francesca
    Efremov, Dimitar G.
    Laurenti, Luca
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1069 - 1076
  • [39] Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics
    Moia, Riccardo
    Patriarca, Andrea
    Mahmoud, Abdurraouf Mokhtar
    Ferri, Valentina
    Favini, Chiara
    Rasi, Silvia
    Deambrogi, Clara
    Gaidano, Gianluca
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (09): : 329 - 342
  • [40] The Evolving Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia
    Dreger, Peter
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) : 355 - +
12345